drugset / Trial / NCT00938236

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236

Phase 3 Terminated 17 enrolled APT Pharmaceuticals, Inc.
NaSingle-groupOpen-labelPrevention

Summary

This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.

Timeline

Start
2009-12
Primary completion
2011-09
Completion
2011-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 300 mg Inhaled